Text Size

A Safety and Tolerability Study of Denufosol in 2-4 Year Olds (REACH-1)

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT01181622
First received: August 12, 2010
Last updated: September 20, 2011
Last verified: September 2011
History of Changes
  Purpose

The purpose of this study is to evaluate the safety and tolerability of denufosol 60 mg TID in pediatric CF patients 2 to 4 years of age


Condition Intervention Phase
Cystic Fibrosis
 Drug: denufosol tetrasodium Inhalation Solution
Drug: 0.9% w/v sodium chloride solution
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC® Star in Patients 2 to 4 Years of Age With Cystic Fibrosis

Resource links provided by NLM:

MedlinePlus related topics: Cystic Fibrosis
U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • Intolerability to study drug as measured by: oxyhemoglobin saturation, treatment-emergent cough, and new wheezes or crackles [ Time Frame: Day 1, Day 7 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Mean change from pre-dose in oxyhemoglobin saturation at defined times post-dose [ Time Frame: Day 1, Day 7 ] [ Designated as safety issue: Yes ]
  • Mean change from baseline in oxyhemoglobin saturation [ Time Frame: Day 7 ] [ Designated as safety issue: Yes ]
  • Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and/or withdrawals due to TEAEs [ Time Frame: Day 7 ] [ Designated as safety issue: Yes ]
  • Mean change from pre-dose in pulse and respiratory rate at defined times post-dose [ Time Frame: Day 1, Day 7 ] [ Designated as safety issue: Yes ]
  • Mean change from baseline in pulse and respiratory rate [ Time Frame: Day 7 ] [ Designated as safety issue: Yes ]
  • Incidence of new medical condition(s) or worsening of previous medical condition(s) from baseline [ Time Frame: Day 7 ] [ Designated as safety issue: Yes ]

Enrollment: 25
Study Start Date: August 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: denufosol tetrasodium Inhalation Solution Drug: denufosol tetrasodium Inhalation Solution
60 mg by oral inhalation three times daily
Placebo Comparator: Placebo Drug: 0.9% w/v sodium chloride solution
0.9% w/v sodium chloride solution by oral inhalation three times daily

  Eligibility

Ages Eligible for Study:   2 Years to 4 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a confirmed diagnosis of CF
  • Have oxyhemoglobin saturation ≥ 95% prior to randomization

Exclusion Criteria:

  • Have acute intercurrent respiratory infection (cough, wheezing, or new rhinorrhea or nasal congestion)
  • Have any significant medical condition not related to CF
  • Unable to discontinue use of hypertonic saline
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01181622

Locations
United States, Illinois
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
United States, Missouri
Saint Louis University
St. Louis, Missouri, United States, 63104
United States, New York
SUNY Upstate Medical University Hospital
Syracuse, New York, United States, 13210
United States, North Carolina
University of North Carolina Hospitals
Chapel Hill, North Carolina, United States, 27514
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Washington
Seattle Childrens's Hospital
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Merck
Investigators
Study Director: Lynn Smiley, MD Medical monitor
  More Information

No publications provided

Responsible Party: Elizabeth Edwards, Senior Director, Inspire Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01181622     History of Changes
Other Study ID Numbers: 08-116, P08643
Study First Received: August 12, 2010
Last Updated: September 20, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
 Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013